



# UNITED STATES PATENT AND TRADEMARK OFFICE

*141*  
UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/716,005	11/18/2003	James R. Uhl	07039-460001	4202

26191 7590 11/29/2006

FISH & RICHARDSON P.C.  
PO BOX 1022  
MINNEAPOLIS, MN 55440-1022

EXAMINER
----------

SITTON, JEHANNE SOUAYA

ART UNIT	PAPER NUMBER
----------	--------------

1634

DATE MAILED: 11/29/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

10/716,005

Applicant(s)

UHL ET AL.

Examiner

Jehanne S. Sitton

Art Unit

1634

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 18 September 2006.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 37-79 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 37-79 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |   |   |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)         | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____                                      |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)         | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____   | 6) <input type="checkbox"/> Other: _____                          |

### **DETAILED ACTION**

1. Currently, newly added claims 37-79 are pending in the instant application. All the amendments and arguments have been thoroughly reviewed but are deemed insufficient to place this application in condition for allowance. The following rejections are newly applied, necessitated by the amendment. They constitute the complete set being presently applied to the instant Application. Response to Applicant's arguments follow. This action is FINAL.
2. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
3. The rejection under 35 USC 112/second paragraph, recited at section 9 of the previous office action is moot in view of the amendment.
4. The rejections under 35 USC 103, made at sections 22-29 of the previous office action are moot in view of the amendment, where each independent claim includes a specific SEQ ID NO:.

### ***Claim Rejections - 35 USC § 112***

5. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

6. Claim 45 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that

Art Unit: 1634

the inventor(s), at the time the application was filed, had possession of the claimed invention.

This is a New Matter Rejection.

Newly added claim 45 claim recites “FRET within 50 cycling steps”, however neither the specification nor the originally filed claims provide support for “50 cycling steps”. The originally filed claims recited within 45, 40 and 30 cycling steps (claims 13-15). The specification has been thoroughly reviewed but does not appear to provide support for “FRET within 50 cycling steps”. Accordingly, this amendment appears to have introduced new matter into the claimed invention.

***Claim Rejections - 35 USC § 103***

7. Claims 37-58 are rejected under 35 U.S.C. 103(a) as being unpatentable over Telford (Telford et al; WO 02/34771; May 2002) in view of Bellin (Bellin et al; Journal of Clinical Microbiology, January 2001, vol. 39, pages 370-374) and further in view of Wittwer I.

Telford teaches that GBS is known to cause serious neonatal infections. Telford teaches nucleic acids from streptococcus group B (GBS) specifically *S. agalactiae*, including SEQ ID NO: 4465 which is the nucleic acid sequence encoding phosphoenolpyruvate phosphotransferase (ptsI). The specification does not define or provide any guidance as to the limitations of “pts”, therefore the term has been given it’s broadest reasonable interpretation to encompass ptsI. Telford teaches to make primers and probes using nucleic acids of GBS (see claims 12 and 19-20 of Telford) to detect Streptococcus in a biological sample (see claims 23 and 24 of Telford, also page 6, lines 8-16). Telford does not teach the detection of GBS in a biological sample using LightCycler™ PCR. However, Bellin teaches a method of successfully detecting E. coli in a

Art Unit: 1634

biological sample using LightCycler™ PCR. With regard to claims 37, 39, 41, and 43, Bellin teaches a method for the multiplex real time (claim 57) PCR detection of Enterohemorrhagic (EHEC) E. coli using a primer pair and two fluorescent hybridization probes to detect the stx1 and stx2 genes (see Table 3). Bellin teaches constructing primers and probes from a known sequence and that FRET hybridization probes were marked with LightCycler™ Red 705 and LightCycler™ Red 640 as acceptor dyes (see page 370, col. 2 “PCR primers and Probes) and fluorescein as the donor (table 3, instant claim 53). The method of Bellin involves continuously monitoring fluorescence and PCR amplification step (45 cycles: “within 50 cycling steps”; instant claim 57), wherein the biological sample is excited at a wavelength absorbed by a donor fluorescent moiety and measuring the wavelength emitted by the acceptor fluorescent moiety (see page 370, para bridging cols 1 and 2; instant claim 54) thereby quantitating the FRET (instant claim 55). Bellin further teaches determining the melting temperature (claim 58) between the stx1 and stx 2 probes wherein the melting temperature confirms the presence or absence of the Shiga toxin or Shiga toxin like producing organism (see figs 1 and 2). Bellin teaches probes which hybridize within no more than 1 nucleotide (instant claims 51 and 52) of each other (table 3), wherein one probe is labeled with a donor fluorescent moiety and the other probe is labeled with an acceptor fluorescent moiety.

Bellin teaches that the method allows for rapid identification of bacteria and complete analysis of up to 32 samples in only 45 minutes.

Therefore it would have been prima facie obvious to one of ordinary skill in the art at time the invention was made to detect GBS using primers and probes to detect ptsI nucleic acids in a biological sample because Telford teaches that GBS causes serious neonatal infections and

Art Unit: 1634

teaches to use nucleic acids from GBS, including *ptsI* to detect bacteria in a sample. It would have further been *prima facie* obvious to the ordinary artisan at the time the invention was made to modify the identification method of Telford to include construction of primers and probes and the FRET detection methods as taught by Bellin for the purpose of providing a rapid method of detecting GBS in a biological sample. The ordinary artisan would have been motivated to modify the method of Telford with the detection methods of Bellin because Bellin teaches that the use of LightCycler™ PCR allows for rapid identification of bacteria and complete analysis of up to 32 samples in only 45 minutes.

With regard to claims 48-49, Bellin teaches that the cycling step was performed on an EHEC strain (EDL933) already known from a previous study (control sample) to carry *stx1* and *stx2*. With regard to claim 50, Bellin teaches multiplexing *stx1* primers and *stx2* probes and *stx2* primers and *stx2* probes were multiplexed in the same assay (see page 372, col. 1), and that the *stx* double producer EDL933 showed amplification product corresponding to *stx1* and *stx2* (control amplification product). Therefore, it would have further been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to include control sequences, including *ptsI* sequences from other strains of *S.agalactiae*, as well as other non *ptsI* nucleic acids to confirm that the primers and probes correctly identified GBS in a sample.

Telford and Bellin do not specifically teach the method wherein the detecting step is performed after each cycling step or wherein the presence of FRET within 40 or 30 cycles is indicative of GBS. However Wittwer I teaches a general method for detecting targets using primer pairs and adjacent FRET probes, wherein the detecting step is performed after each cycling step (see col 6, lines 33-35, col 16, lines 7-10; instant claim 56). Further, Wittwer I

Art Unit: 1634

teaches target detection after 30 and 26 cycles (col. 19 lines 14-16 and col. 20, lines 30-35; instant claims 46 and 47). Therefore, it would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to improve the method of Telford and Bellin by detecting FRET after each cycling step for the purpose of detecting GBS as rapidly as possible. The ordinary artisan would have been motivated to improve the method of Telford and Bellin because Wittwer I teaches the successful identification of targets in as few as 30 and 26 cycles.

Telford and Bellin do not teach primers and probes *comprising* SEQ ID NOS 1-4, or primers and probes which are no longer than 30 nucleotides in length and comprising one of SEQ ID NOS: 1-4, however, Wittwer I teaches generally how to design probes for the method (col. 11, line 50-col. 12, line 39). Wittwer I also teaches that the primers are preferably 15-30 nucleotides long and that the probes can be 15-50 nucleotides long (see col. 11, lines 41-59) and exemplifies probes that are 30 nucleotides (SEQ ID NO: 6 of Wittwer I). Additionally, the primers and probes taught by Bellin are no longer than 30 nucleotides in length (see table 3).

In performing the method of Telford in view of Bellin, the ordinary artisan would be motivated to construct primers and probes as taught by Bellin for detection of GBS sequences as taught by Telford. With regard to claims 37-44, instantly claimed SEQ ID NOS 1-4 are found within SEQ ID NO: 4465 of Telford as follows: SEQ ID NO: 1 is identical to positions 177-199 of SEQ ID NO: 4465, SEQ ID NO: 2 is the reverse complement of positions 357-377 of SEQ ID NO: 4465, SEQ ID NO: 3 is identical to positions 265-289 of SEQ ID NO: 4465, and SEQ ID NO: 4 is identical to positions 292-311 of SEQ ID NO: 4465. Designing primers and probes to known sequences taught in the art is routine experimentation. The prior art teaches the

Art Unit: 1634

parameters and objectives involved in the selection of oligonucleotides that function as probes and primers, see Wittwer I. Moreover there are many internet web sites that provide free downloadable software to aid in the selection of primers drawn from genetic data recorded in a spreadsheet. The prior art is replete with guidance and information necessary to permit the ordinary artisan in the field of nucleic acid detection to design primers and probes. As discussed above, the ordinary artisan would be motivated to have designed and tested primers and probes that function to detect GBS as taught by Telford, including the instantly claimed nucleic acid sequences comprising SEQ ID NOS 1-4, as well as primers and probes which comprise one of SEQ ID NOS 1-4, which is no longer than 30 nucleotides in length. These sequences are obvious over the teachings of Telford and Bellin in view of Wittwer I. It is noted that an assay using a primer pair consisting of SEQ ID NOS 1-2, with probes consisting of SEQ ID NOS 3 and 4, respectively, did not cross react with other non GBS bacteria, which is unexpected over the teaches of Telford and Bellin in view of Wittwer. The claims, however, are not limited to these SEQ ID NOS due to the recitation of "comprising" as well as the upper length limitation.

8. Claims 59-61 are rejected under 35 U.S.C. 103(a) as being unpatentable over Telford in view of Bellin , further in view of Wittwer I, as applied to claims 37-58 above, and further in view of Hartley (US Patent 5,035,996; 7/30/1991).

The teachings of Telford in view of Bellin and further in view of Wittwer I are set forth above.

Telford, Bellin and Wittwer I do not teach the method comprising preventing amplification of a contaminant nucleic acid by performing amplification in the presence of uracil and treating the sample with uracil-DNA glycosylase prior to amplification, however Hartley



Art Unit: 1634

teaches preventing amplification of contaminants by treating samples with uracil DNA glycosylase prior to amplification, and also performing amplification in the presence of uracil. Therefore, it would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to improve the method of Telford, Bellin, and Wittwer I by preventing amplification of contaminating nucleic acids with the method of preventing amplification of contaminants taught by Hartley for the purpose of making the method of Telford, Bellin, and Wittwer I more accurate.

9. Claim 62 is rejected under 35 U.S.C. 103(a) as being unpatentable over Telford in view of Bellin, further in view of Wittwer I as applied to claims 37-58 above, and further in view of Bergeron (Bergeron et al; New England Journal of Medicine, 2000, vol. 343, pages 175-179).

The teachings of Telford in view of Bellin, and further in view of Wittwer I, are set forth above.

Telford, Bellin and Wittwer I do not teach a method of nucleic acid based GBS identification in a biological sample wherein the sample is an anal/and or vaginal swab. However, Bergeron teaches studying the efficacy of PCR assays for routine screening of pregnant women for GBS at the time of delivery. Bergeron teaches obtaining anal, vaginal, and combined anal/vaginal specimens and successfully detecting GBS (see abstract). Bergeron teaches that the sensitivity of the PCR results was 97%. Therefore, it would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to modify the method of PCR based detection of GBS of Telford, Bellin, and Wittwer I to include anal and/or vaginal sample specimens as taught by Bergeron. The ordinary artisan would have been motivated to use anal and/or vaginal specimens because Bergeron teaches that such specimens

Art Unit: 1634

allow for the sensitivity detection of GBS in pregnant women at the time of delivery with a negative predictive value of 98.8%.

10. Claims 74-77 are rejected under 35 USC 103(a) as being unpatentable over Telford in view of Bellin and Buck (Buck et al Biotechniques (1999) 27(3):528-536).

Telford teaches that GBS is known to cause serious neonatal infections. Telford teaches nucleic acids from streptococcus group B (GBS) specifically *S. agalactiae*, including SEQ ID NO: 4465 which is the nucleic acid sequence encoding phosphoenolpyruvate phosphotransferase (ptsI). The specification does not define or provide any guidance as to the limitations of “pts”, therefore the term has been given it’s broadest reasonable interpretation to encompass ptsI. Telford teaches to make primers using nucleic acids of GBS (see claims 12 and 19-20 of Telford) to detect Streptococcus in a biological sample (see claims 23 and 24 of Telford, also page 6, lines 8-16). Telford does not teach the detection of GBS in a biological sample using LightCycler™ PCR. However, Bellin teaches a method of successfully detecting E. coli in a biological sample using LightCycler™ PCR. Bellin teaches a real time single PCR assay for detecting EHEC using a primer pair to detect stx1 and stx2 wherein the amplification product is contacted with SYBR Green I, a double stranded nucleic acid binding dye (see page 370, col. 1, last para; and page 372, col. 1 “PCR optimization and sensitivity”). The method of Bellin involves continuously monitoring fluorescence and PCR amplification step wherein the biological sample is excited at a wavelength absorbed by a donor fluorescent moiety and measuring the wavelength emitted by the acceptor fluorescent moiety thereby quantitating the FRET. Bellin teaches that the method

Art Unit: 1634

allows for rapid identification of bacteria and complete analysis of up to 32 samples in only 45 minutes.

Therefore it would have been prima facie obvious to one of ordinary skill in the art at time the invention was made to detect GBS using primers and a double stranded DNA binding dye to detect ptsI nucleic acids in a biological sample because Telford teaches that GBS causes serious neonatal infections and teaches to use nucleic acids from GBS, including ptsI to detect bacteria in a sample. It would have further been prima facie obvious to the ordinary artisan at the time the invention was made to modify the identification method of Telford to include construction of primers and detection of double stranded DNA using a double stranded DNA binding dye as taught by Bellin for the purpose of providing a rapid method of detecting GBS in a biological sample. The ordinary artisan would have been motivated to modify the method of Telford with the detection methods of Bellin because Bellin teaches that the use of LightCycler™ PCR allows for rapid identification of bacteria and complete analysis of up to 32 samples in only 45 minutes.

In performing the method of Telford in view of Bellin, the ordinary artisan would be motivated to construct primers from the sequence taught by Telford. With regard to claims 74-77, Telford and Bellin do not teach primers comprising a sequence of SEQ ID NO: 1 or 2, however instantly claimed SEQ ID NOS 1-2 are found within SEQ ID NO: 4465 of Telford as follows: SEQ ID NO: 1 is identical to positions 177-199 of SEQ ID NO: 4465, SEQ ID NO: 2 is the reverse complement of positions 357-377 of SEQ ID NO: 4465. Further, Buck expressly provides evidence of the equivalence of primers in amplifying sequences. Specifically, Buck invited primer submissions from a number of labs (39) (page 532, column 3), with 69 different

Art Unit: 1634

primers being submitted (see page 530, column 1). Buck also tested 95 primers spaced at 3 nucleotide intervals along the entire sequence at issue, thereby testing more than 1/3 of all possible 18 mer primers on the 300 base pair sequence (see page 530, column 1). When Buck tested each of the primers selected by the methods of the different labs, Buck found that every single primer worked (see page 533, column 1). Only one primer ever failed, No. 8, and that primer functioned when repeated. Further, every single control primer functioned as well (see page 533, column 1). Buck expressly states "The results of the empirical sequencing analysis were surprising in that nearly all of the primers yielded data of extremely high quality (page 535, column 2)." Therefore, Buck provides direct evidence that all primers would be expected to function, and in particular, all primers selected according to the ordinary criteria, however different, used by 39 different laboratories. It is particularly striking that all 95 control primers functioned, which represent 1/3 of all possible primers in the target region. This clearly shows that every primer would have a reasonable expectation of success in amplification of the target it is designed to amplify and detect.

Therefore, it would have been *prima facie* obvious to the ordinary artisan at the time the invention was made to construct primers for performing the method of Telford and Bellin, including primers comprising SEQ ID NOS 1 and 2. Designing primers and probes to known sequences taught in the art is routine experimentation. The prior art teaches the parameters and objectives involved in the selection of oligonucleotides that function as primers. Moreover there are many internet web sites that provide free downloadable software to aid in the selection of primers drawn from genetic data recorded in a spreadsheet. The prior art is replete with guidance and information necessary to permit the ordinary artisan in the field of nucleic acid detection to

Art Unit: 1634

design primers and probes. As discussed above, the ordinary artisan would be motivated to have designed and tested primers and probes that function to detect GBS as taught by Telford, including the instantly claimed nucleic acid sequences comprising SEQ ID NOS 1-2. These sequences are obvious over the teachings of Telford in view of Bellin and Buck.

11. Claims 78-79 are rejected under 35 USC 103(a) as being unpatentable over Telford in view of Bellin and Buck, as applied to claims 74-77 above, and further in view of Wittwer II (Wittwer et al; US Patent 6,174,670; 1/16/2001).

The teachings of Telford in view of Bellin and Buck are set forth above.

Telford, Bellin and Buck do not teach determining the melting temperature between the amplification product and the double stranded nucleic acid binding dye, however Wittwer II teaches determining the melting temperature between the amplification product and double stranded binding dye for the purpose of correcting for nonspecific amplification, improving sensitivity of PCR, monitoring product hybridization, and product quantification by reannealing kinetics (col. 3, lines 30-50). Wittwer II specifically teaches a method of real time monitoring of a PCR reaction by amplifying the target by PCR in the presence of SYBR Green I, exciting the biological sample with light and detecting the emission, and monitoring the temperature dependent fluorescence from SYBR Green I (see col. 7, lines 13-31). Further, Wittwer II specifically teaches analysis using the DNA binding dye ethidium bromide (see col. 11, lines 10-38; col. 22, lines 54-66). Therefore, it would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to improve the method of detection of GBS of Telford, Bellin and Buck to include the step of determining the melting temperature between the amplification product and double stranded binding dye, for the purpose of correcting for

Art Unit: 1634

nonspecific amplification, improving sensitivity of PCR, monitoring product hybridization, and product quantification by reannealing kinetics, as taught by Wittwer II.

12. Claims 63-68, 72 and 73 are rejected under 35 U.S.C. 103(a) as being unpatentable over Telford in view of Belanger (Belanger et al; Journal of Clinical Microbiology, vol. 40, pages 1436-1440, April 2002) and further in view of Buck and Tyagi (Tyagi et al; US Patent 5,925,517).

Telford teaches that GBS is known to cause serious neonatal infections. Telford teaches nucleic acids from streptococcus group B (GBS) specifically *S. agalactiae*, including SEQ ID NO: 4465 which is the nucleic acid sequence encoding phosphoenolpyruvate phosphotransferase (ptsI). Telford teaches to make primers and probes using nucleic acids of GBS for (see claims 12 and 19-20 of Telford) to detect Streptococcus in a biological sample (see claims 23 and 24 of Telford, also page 6, lines 8-16). Telford does not teach the detection of GBS in a biological sample using PCR followed by hybridization with a molecular beacon probe labeled with a donor and corresponding acceptor fluorescent moiety.

However, Belanger teaches a method for the detection of shiga toxin producing *E. coli* by detection of the stx1 and stx2 genes (Shiga like toxin producing organism). The method of Belanger uses a pair of primers to amplify either stx1 or stx2 (amplification step) and a molecular beacon probe (hybridizing step) to detect the presence of the *E. coli* strains which do contain the stx1 or stx2 genes and distinguish them from strains that do not (see page 1438, col. 1), using the presence or absence of fluorescence for detection. It is noted that molecular beacon probes comprise a single stranded sequence which permits secondary structure formation

Art Unit: 1634

(hairpin) wherein the secondary structure results in spatial proximity between the donor and acceptor fluorescent moiety. Further, the acceptor moiety in a molecular beacon probe is a quencher. Belanger teaches that the method is rapid, simple and sensitive and allowed detection of bacteria in a sample where the bacteria were not detected by conventional culture methods (see abstract).

Therefore, it would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to detect GBS using primers and probes to detect ptsI nucleic acids in a biological sample because Telford teaches that GBS causes serious neonatal infections and teaches to use nucleic acids from GBS, including ptsI to detect bacteria in a sample. It would have further been prima facie obvious to the ordinary artisan at the time the invention was made to modify the identification method of Telford to include construction of primers and a molecular beacon probe and the fluorescence based PCR methods as taught by Belanger for the purpose of providing a rapid method of detecting GBS in a biological sample. The ordinary artisan would have been motivated to modify the method of Telford with the detection methods of Belanger because Belanger teaches that the use of a molecular beacon probe in a fluorescence based PCR detection method allows for rapid, simple and sensitive identification of bacteria.

Telford and Belanger do not teach primers and probes comprising SEQ ID NOS: 1-4, however in performing the method of Telford and Belanger, the ordinary artisan would be motivated to construct primers and probes for use in the method. Tyagi teaches the use of hairpin probes for target detection and teaches that the target complementary portion of the probe can be 15-35 nucleotides long, while the arm (self complementary stem) length can be from 3-25 nucleotides in length (see col. 12, lines 47-55). Further, Buck expressly provides evidence of the

Art Unit: 1634

equivalence of primers in amplifying sequences. Specifically, Buck invited primer submissions from a number of labs (39) (page 532, column 3), with 69 different primers being submitted (see page 530, column 1). Buck also tested 95 primers spaced at 3 nucleotide intervals along the entire sequence at issue, thereby testing more than 1/3 of all possible 18 mer primers on the 300 base pair sequence (see page 530, column 1). When Buck tested each of the primers selected by the methods of the different labs, Buck found that every single primer worked (see page 533, column 1). Only one primer ever failed, No. 8, and that primer functioned when repeated. Further, every single control primer functioned as well (see page 533, column 1). Buck expressly states “The results of the empirical sequencing analysis were surprising in that nearly all of the primers yielded data of extremely high quality (page 535, column 2).” Therefore, Buck provides direct evidence that all primers would be expected to function, and in particular, all primers selected according to the ordinary criteria, however different, used by 39 different laboratories. It is particularly striking that all 95 control primers functioned, which represent 1/3 of all possible primers in the target region. This clearly shows that every primer would have a reasonable expectation of success in amplification of the target it is designed to amplify and detect.

Therefore it would have been *prima facie* obvious to the one of ordinary skill in the art at the time the invention was made to construct a number of primers and probes for use in the method of Telford in view of Belanger. With regard to claims 63-68, instantly claimed SEQ ID NOS 1-4 are found within SEQ ID NO: 4465 of Telford as follows: SEQ ID NO: 1 is identical to positions 177-199 of SEQ ID NO: 4465, SEQ ID NO: 2 is the reverse complement of positions 357-377 of SEQ ID NO: 4465, SEQ ID NO: 3 is identical to positions 265-289 of SEQ ID NO:



Art Unit: 1634

4465, and SEQ ID NO: 4 is identical to positions 292-311 of SEQ ID NO: 4465. Designing primers and probes to known sequences taught in the art is routine experimentation. The prior art teaches the parameters and objectives involved in the selection of oligonucleotides that function as probes and primers, see Tyagi and Buck. Moreover there are many internet web sites that provide free downloadable software to aid in the selection of primers drawn from genetic data recorded in a spreadsheet. The prior art is replete with guidance and information necessary to permit the ordinary artisan in the field of nucleic acid detection to design primers and probes. As discussed above, the ordinary artisan would be motivated to have designed and tested primers and probes that function to detect GBS as taught by Telford in view of Belanger, including the instantly claimed nucleic acid sequences comprising SEQ ID NOS 1-4. These sequences are considered obvious over the teachings of Telford and Bellin in view of Tyagi and Buck.

13. Claims 63-69 are rejected under 35 U.S.C. 103(a) as being unpatentable over Telford in view of Pfeffer (Pfeffer et al; WO 98/48046) and Buck.

Telford teaches that GBS is known to cause serious neonatal infections. Telford teaches nucleic acids from streptococcus group B (GBS) specifically *S. agalactiae*, including SEQ ID NO: 4465 which is the nucleic acid sequence encoding phosphoenolpyruvate phosphotransferase (ptsI). Telford teaches to make primers and probes using nucleic acids of GBS for (see claims 12 and 19-20 of Telford) to detect Streptococcus in a biological sample (see claims 23 and 24 of Telford, also page 6, lines 8-16). Telford does not teach the detection of GBS in a biological sample using a PCR assay that employs the 5'-3' exonuclease activity of Taq polymerase.

However, Pfeffer teaches a method of detecting enterohemorrhagic E. coli by using a PCR assay that employs the 5'-3' exonuclease activity of Taq polymerase (TAQMAN™) together with a fluorescent probe (see page 4, lines 18-23; page 5, lines 24-26; page 9, lines 5-10). Pfeffer teaches that the method utilizes primers (page 8, lines 21-30) and a probe (page 10, lines 15-24) for the detection of the SltI and SltII wherein detection of the presence of fluorescence resonance energy transfer is indicative of the presence of the enterohemorrhagic E. coli (see also, page 25-26 and tables 2-4). Pfeffer teaches that the use of the TAQMAN™ assay allows for the specific, rapid and high throughput detection of specific bacteria.

Therefore it would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to detect GBS using primers and a probe to detect ptsI nucleic acids in a biological sample because Telford teaches that GBS causes serious neonatal infections and teaches to use nucleic acids from GBS, including ptsI to detect bacteria in a sample. It would have further been prima facie obvious to the ordinary artisan at the time the invention was made to modify the identification method of Telford to include construction of primers and a fluorescent probe as taught by Pfeffer for the purpose of providing a rapid method of detecting GBS in a biological sample. The ordinary artisan would have been motivated to modify the method of Telford with the detection methods of Pfeffer because Pfeffer teaches that the use of a fluorescently labeled probe in a TAQMAN™ detection method allows for rapid, simple and sensitive identification of bacteria.

Telford and Pfeffer do not teach primers and probes comprising SEQ ID NOS: 1-4, however in performing the method of Telford and Pfeffer, the ordinary artisan would be motivated to construct primers and probes for use in the method. Pfeffer teaches the construction

Art Unit: 1634

of primer and probes for use in the method and Buck expressly provides evidence of the equivalence of primers in amplifying sequences. Specifically, Buck invited primer submissions from a number of labs (39) (page 532, column 3), with 69 different primers being submitted (see page 530, column 1). Buck also tested 95 primers spaced at 3 nucleotide intervals along the entire sequence at issue, thereby testing more than 1/3 of all possible 18 mer primers on the 300 base pair sequence (see page 530, column 1). When Buck tested each of the primers selected by the methods of the different labs, Buck found that every single primer worked (see page 533, column 1). Only one primer ever failed, No. 8, and that primer functioned when repeated. Further, every single control primer functioned as well (see page 533, column 1). Buck expressly states "The results of the empirical sequencing analysis were surprising in that nearly all of the primers yielded data of extremely high quality (page 535, column 2)." Therefore, Buck provides direct evidence that all primers would be expected to function, and in particular, all primers selected according to the ordinary criteria, however different, used by 39 different laboratories. It is particularly striking that all 95 control primers functioned, which represent 1/3 of all possible primers in the target region. This clearly shows that every primer would have a reasonable expectation of success in amplification of the target it is designed to amplify and detect.

Therefore it would have been prima facie obvious to the one of ordinary skill in the art at the time the invention was made to construct a number of primers and probes for use in the method of Telford in view of Pfeffer. With regard to claims 63-68, instantly claimed SEQ ID NOS 1-4 are found within SEQ ID NO: 4465 of Telford as follows: SEQ ID NO: 1 is identical to positions 177-199 of SEQ ID NO: 4465, SEQ ID NO: 2 is the reverse complement of positions

Art Unit: 1634

357-377 of SEQ ID NO: 4465, SEQ ID NO: 3 is identical to positions 265-289 of SEQ ID NO: 4465, and SEQ ID NO: 4 is identical to positions 292-311 of SEQ ID NO: 4465. Designing primers and probes to known sequences taught in the art is routine experimentation. The prior art teaches the parameters and objectives involved in the selection of oligonucleotides that function as probes and primers, see Pfeffer and Buck. Moreover there are many internet web sites that provide free downloadable software to aid in the selection of primers drawn from genetic data recorded in a spreadsheet. The prior art is replete with guidance and information necessary to permit the ordinary artisan in the field of nucleic acid detection to design primers and probes. As discussed above, the ordinary artisan would be motivated to have designed and tested primers and probes that function to detect GBS as taught by Telford in view of Pfeffer, including the instantly claimed nucleic acid sequences comprising SEQ ID NOS 1-4. These sequences are considered obvious over the teachings of Telford in view of Pfeffer and Buck.

14. Claims 70-71 are rejected under 35 U.S.C. 103(a) as being unpatentable over Telford in view of Pfeffer and Buck as applied to claims 63-69 above, and further in view of Livak et al (US Patent 5,538,848 1995).

The teachings of Telford, Pfeffer and Buck are set forth above.

Telford, Pfeffer, and Buck do not teach a method wherein the donor and acceptor moieties are within no more than 5 nucleotides of each other on the probe, however, Livak teaches a method of detecting hybridization of flourogenic probe in a 5' nucleic assay, and teaches that traditionally, the donor and quencher are separated by about 6-16 nucleotides of each other on the probe (see col. 2, lines 45-50). The recitation of "about 6" has been interpreted to encompass 5 nucleotides apart. Therefore, it would have been prima facie obvious to one of

Art Unit: 1634

ordinary skill in the art at the time the invention was made to modify the method of Telford, Pfeffer and Buck to use probes wherein the donor and quencher are within no more than 5 nucleotides of each other because Livak teaches that such orientation provides sufficient spacing for the purposes of detecting hybridization of the probe in the 5' nuclease (Taqman) assay. The ordinary artisan would have been motivated to modify the probe used by Telford, Pfeffer, and Buck as taught by Livak for the purpose of making the method of Telford, Pfeffer, and Buck more versatile to perform.

15. Claims 37-61 and 63-79 are rejected under 35 U.S.C. 103(a) as being unpatentable over Telford in view of Uhl (Uhl et al; US patent 6,593,093).

The applied reference has a common inventor with the instant application. Based upon the earlier effective U.S. filing date of the reference, it constitutes prior art only under 35 U.S.C. 102(e). This rejection under 35 U.S.C. 103(a) might be overcome by: (1) a showing under 37 CFR 1.132 that any invention disclosed but not claimed in the reference was derived from the inventor of this application and is thus not an invention "by another"; (2) a showing of a date of invention for the claimed subject matter of the application which corresponds to subject matter disclosed but not claimed in the reference, prior to the effective U.S. filing date of the reference under 37 CFR 1.131; or (3) an oath or declaration under 37 CFR 1.130 stating that the application and reference are currently owned by the same party and that the inventor named in the application is the prior inventor under 35 U.S.C. 104, together with a terminal disclaimer in accordance with 37 CFR 1.321(c). *This rejection might also be overcome by showing that the*

Art Unit: 1634

*reference is disqualified under 35 U.S.C. 103(c) as prior art in a rejection under 35 U.S.C. 103(a). See MPEP § 706.02(l)(1) and § 706.02(l)(2).*

Telford teaches that GBS is known to cause serious neonatal infections. Telford teaches nucleic acids from streptococcus group B (GBS) specifically *S. agalactiae*, including SEQ ID NO: 4465 which is the nucleic acid sequence encoding phosphoenolpyruvate phosphotransferase (ptsI). Telford teaches to make primers and probes using nucleic acids of GBS (see claims 12 and 19-20 of Telford) to detect Streptococcus in a biological sample (see claims 23 and 24 of Telford, also page 6, lines 8-16). Telford does not teach the detection of GBS in a biological sample using LightCycler™ PCR, molecular beacon probes, or the TAQMAN™ assay. However, Uhl teaches a method of successfully detecting Group A Streptococcus (GAS) in a biological sample by using primers and probes to *ptsI* nucleic acids using various methods including LightCycler™ PCR, molecular beacon probes, or the TAQMAN™ assay (see claims 1-21 and 27-35 of Uhl). Further Uhl teaches that primers and probes are 8-50 nucleotides, including up to 30 nucleotides in length (see col. 5). Therefore, it would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to detect GBS using primers and a probes to detect *ptsI* nucleic acids in a biological sample because Telford teaches that GBS causes serious neonatal infections and teaches to use nucleic acids from GBS, including *ptsI* to detect bacteria in a sample. It would have further been prima facie obvious to the ordinary artisan at the time the invention was made to modify the identification method of Telford to include construction of primers and probes for use in LightCycler™ PCR, molecular beacon probe assays, and the TAQMAN™ assay as taught by Uhl for the purpose of providing a method of detecting GBS in a biological sample. The ordinary artisan would have been

Art Unit: 1634

motivated to modify the method of Telford with the detection methods of Uhl because Uhl teaches that the use of LightCycler™ PCR, molecular beacon probe assays, and the TAQMAN™ allows for sensitive identification of streptococcus bacteria.

Additionally, instantly claimed SEQ ID NO: 2 is identical to SEQ ID NO: 2 of Uhl. Telford and Uhl do not teach primers and probes *comprising* SEQ ID NOS 1, and 3-4, however, in performing the method of Telford in view of Uhl, the ordinary artisan would be motivated to construct primers and probes as taught by Uhl for detection of GBS sequences as taught by Telford. Instantly claimed SEQ ID NOS 1-4 are found within SEQ ID NO: 4465 of Telford as follows: SEQ ID NO: 1 is identical to positions 177-199 of SEQ ID NO: 4465, SEQ ID NO: 2 is the reverse complement of positions 357-377 of SEQ ID NO: 4465, SEQ ID NO: 3 is identical to positions 265-289 of SEQ ID NO: 4465, and SEQ ID NO: 4 is identical to positions 292-311 of SEQ ID NO: 4465. Designing primers and probes to known sequences taught in the art is routine experimentation. The prior art teaches the parameters and objectives involved in the selection of oligonucleotides that function as probes and primers, see Uhl. Moreover there are many internet web sites that provide free downloadable software to aid in the selection of primers drawn from genetic data recorded in a spreadsheet. The prior art is replete with guidance and information necessary to permit the ordinary artisan in the field of nucleic acid detection to design primers and probes. As discussed above, the ordinary artisan would be motivated to have designed and tested primers and probes that function to detect GBS as taught by Telford, including the instantly claimed nucleic acid sequences comprising SEQ ID NOS 1-4 as well as primers and probes which are no longer than 30 nucleotides in length and comprise one of SEQ ID NOS 1-4.

Art Unit: 1634

16. Claim 62 is rejected under 35 U.S.C. 103(a) as being unpatentable over Telford in view of Uhl as applied to claims 37-61 above, and further in view of Bergeron (Bergeron et al; New England Journal of Medicine, 2000, vol. 343, pages 175-179).

The teachings of Telford in view of Uhl are set forth above.

Telford and Uhl do not teach a method of nucleic acid based GBS identification in a biological sample wherein the sample is an anal/and or vaginal swab. However, Bergeron teaches studying the efficacy of PCR assays for routine screening of pregnant women for GBS at the time of delivery. Bergeron teaches obtaining anal, vaginal, and combined anal/vaginal specimens and successfully detecting GBS (see abstract). Bergeron teaches that the sensitivity of the PCR results was 97%. Therefore, it would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to modify the method of PCR based detection of GBS of Telford and Uhl, to include anal and/or vaginal sample specimens as taught by Bergeron. The ordinary artisan would have been motivated to use anal and/or vaginal specimens because Bergeron teaches that such specimens allow for the sensitivity detection of GBS in pregnant women at the time of delivery with a negative predictive value of 98.8%.

### ***Response to Arguments***

17. The response at page 14, with regard to "Rejection 1" (Telford in view of Bellin and Further in view of Wittwer I) asserts that the new claims recite a particular primer or probe sequence, requiring that they be not more than 30 nucleotides in length and that none of the cited reference alone or in combination teach or suggest the particular primer and probe sequences. This argument has been thoroughly reviewed but was not found persuasive. The claims are not



Art Unit: 1634

limited to a particular primer or probe sequence as the claims continue to recite “comprising” language, all be it with an upper length limitation. However, this genus of sequences include lengths that are routinely used in the prior art as primers and probes as evidenced by the prior art cited above. The prior art provides ample guidance to construct primers and probes from known sequences for use in the claimed methods, including the sequence from which to construct the primers and probes. As noted in the previous office action, with regard to claims 37-62, the specification teaches that an assay using a primer pair consisting of SEQ ID NOS 1-2, with probes consisting of SEQ ID NOS 3 and 4, respectively, did not cross react with other non GBS bacteria, which is unexpected over the teaches of Telford and Bellin in view of Wittwer I. The claims, however, are not limited to these SEQ ID NOS due to the continued recitation of “comprising”, which allows for variability on either side of the recited SEQ ID NOS, albeit with an upper length limitation. The encompassed variability, however, would be expected to alter the properties of SEQ ID NOS 1-4, as the addition of nucleotides on either side of the SEQ ID NO would change the length and GC content of the primers and probes, thus affecting the  $T_m$  of the oligonucleotides, and therefore their hybridization specificity. As noted in the MPEP, the scope of the unexpected results must be commensurate in scope with the claimed invention.

**716.02(d) Unexpected Results Commensurate in Scope With Claimed Invention:**

Whether the unexpected results are the result of unexpectedly improved results or a property not taught by the prior art, the “objective evidence of nonobviousness must be commensurate in scope with the claims which the evidence is offered to support.”

With regard to “Rejection 2”, the response asserts that the claims are distinguished from Telford in view of Uhl. The response asserts that Uhl is directed to detecting GAS while the instant claims are directed to detecting GBS, and that although SEQ ID NO: 2 can be used to target both, the particular primer and probe sequences to detect each bacteria are different. This

Art Unit: 1634

argument has been thoroughly reviewed but was found unpersuasive. The claims are not limited to the particular primer and probes taught in the specification for detection of GBS, as the claims continue to encompass sequences with variability on either side, albeit with an upper length limitation. Further the independent claims, as well as dependent claims 38, 40, 42, and 44, although reciting a particular SEQ ID NO:, are not limited to any particular combination of primers and probes. The fact that SEQ ID NO: 2 can be used to detect both GAS and GBS illustrates that the use of the sequences in combination, as taught in the specification, provides for the particular specificity illustrated. For these reasons and the reasons made above, the rejections are maintained from the previous office action and applied to the newly added claims.

### *Conclusion*

18. No claims are allowed.

19. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event,

Art Unit: 1634

however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

20. Any inquiry concerning this communication or earlier communications from the examiner should be directed to examiner Jehanne Sitton whose telephone number is (571) 272-0752. The examiner can normally be reached Monday-Thursday from 8:00 AM to 5:00 PM and on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla, can be reached on (571) 272-0735. The fax phone number for this Group is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.



Jehanne Sitton  
Primary Examiner  
Art Unit 1634

11/27/06